Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | Opicapone shows better motor performance in Parkinson’s disease compared to entacapone

Joaquim Ferreira • 4 Sep 2020
MDS 2020
Movement Disorders Parkinson's Disease Entacapone Levodopa Opicapone
BIPARK-I BIPARK-II

Joaquim Ferreira, MD, PhD, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, discusses how the newly licensed COMT inhibitor opicapone has shown to have more benefits over the older treatment entacapone. Opicapone displays better motor performance by prolonging the ‘on-time’ in Parkinson’s disease patients. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).

More from Joaquim Ferreira

1:43
Update on the ADOPTION study: opicapone in Parkinson’s disease
Joaquim Ferreira • 29 Aug 2023
1:19
Combining non-pharmacological treatments with pharmacotherapies for PD
Joaquim Ferreira • 29 Aug 2023
1:49
How dose and regimen impact levodopa bioavailability
Joaquim Ferreira • 29 Aug 2023
2:24
The importance of clinical trials in generating evidence for safe and effective therapies
Joaquim Ferreira • 29 Aug 2023

Related Videos

1:58
Ambroxol & other targeted therapies in Parkinson's
K Ray Chaudhuri • 21 Mar 2024
3:00
The use of precision medicine in Parkinson’s disease
K Ray Chaudhuri • 21 Mar 2024
3:19
An update on the dashboard of vitals in Parkinson's: working towards global implementation
K Ray Chaudhuri • 21 Mar 2024
2:09
Parkinson's beyond dopamine: the role of acetylcholine, noradrenaline, and serotonin
K Ray Chaudhuri • 21 Mar 2024
The content of VJNeurology is intended for healthcare professionals